Related Experiment Videos

Role of P-glycoprotein in dolastatin 10 resistance

D L Toppmeyer1, C A Slapak, J Croop

  • 1Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.

Insights

Dolastatin 10, an antitumor peptide, shows cross-resistance in multidrug resistance (MDR) cells. This resistance is reversed by verapamil and linked to P-glycoprotein (P-gp) interaction.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Cancer Research

Background:

  • Dolastatin 10, a cytotoxic pentapeptide from Dolabella auricularia, possesses potent antitumor properties.
  • Multidrug resistance (MDR) is a significant challenge in cancer chemotherapy, limiting the efficacy of cytotoxic agents.
  • P-glycoprotein (P-gp) is a key efflux pump implicated in MDR.

Purpose of the Study:

  • To investigate the mechanism of resistance to Dolastatin 10 in cancer cells.
  • To determine the role of P-glycoprotein (P-gp) in mediating resistance to Dolastatin 10.
  • To explore the potential of verapamil in reversing Dolastatin 10 resistance.

Main Methods:

  • Utilized murine PC4 and human U-937 leukemia cell lines exhibiting MDR phenotype.
  • Employed a Chinese hamster ovary (CHO) cell line transfected with human mdr1 cDNA to study P-gp function.
  • Assessed Dolastatin 10 resistance and its reversal by verapamil.
  • Performed photoaffinity labeling of P-gp in the presence of Dolastatin 10.

Main Results:

  • Murine PC4 and human U-937 leukemia cells with MDR phenotype demonstrated cross-resistance to Dolastatin 10.
  • Verapamil effectively reversed the observed resistance to Dolastatin 10.
  • CHO cells transfected with human mdr1 cDNA expressing P-gp showed verapamil-sensitive resistance to Dolastatin 10.
  • Photoaffinity labeling indicated a decreased interaction with P-gp in the presence of Dolastatin 10.

Conclusions:

  • P-glycoprotein (P-gp) confers, at least partially, resistance to Dolastatin 10.
  • Dolastatin 10 is identified as a novel agent associated with the multidrug resistance (MDR) phenotype.
  • These findings suggest potential strategies for overcoming Dolastatin 10 resistance in cancer therapy.

Related Concept Videos